Interleukin-2 continues to show promise as HIV therapy.
D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count / Q000187:drug effects*; D017322:Clinical Trials, Phase II as Topic; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000097:blood / Q000276:immunology / Q000628:therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007167:Immunotherapy; D019469:Indinavir / Q000009:adverse effects / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014779:Virus Replication / Q000187:drug effects
D000998:Antiviral Agents; D017320:HIV Protease Inhibitors; D007376:Interleukin-2; D019469:Indinavir